Response to neo-adjuvant chemotherapy and outcomes for I-SPY 1 patients stratified by the 70-gene prognosis signature (MammaPrint) and molecular subtyping (BluePrint)

Publication Name: Cancer Research, Poster

Author(s): Stefan Glück, Femke de Snoo, Sun Tian, Annuska Glas, Laura van 't Veer

Classification of breast cancers into molecular subtypes may be important for the proper selection of therapy for patients as tumors with seemingly similar biology can have strikingly different clinical outcomes. The multi-center neo-adjuvant I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657) … Continued

NBRST – Prospective neo-adjuvant registry trial linking MammaPrint, subtyping and treatment response: Neoadjuvant Breast Registry – Symphony Trial

Publication Name: Cancer Research

Author(s): Pat Whitworth, Mark Gittleman, Stephanie Akbari, Bichlien Nguyen, Paul Baron, Michael Rotkiss, Jennifer Beatty, Jessica Gibson, Lisette Stork-Sloots, Femke de Snoo, Peter Beitsch

The scope of this registry study is to measure chemosensitivity as defined by pCR (primary endpoint), or endocrine sensitivity as defined by partial response (decrease in longest tumor diameter or residual cancer burden category 1 (RCB1), a primary endpoint for … Continued

The EORTC 10041/BIG 03-04 MINDACT trial is feasible: Results of the pilot phase

Publication Name: EUROPEAN JOURNAL OF CANCER

Author(s): Emiel Rutgers, Martine J. Piccart-Gebhart, Jan Bogaerts, Suzette Delaloge, Laura Van ‘t Veer

Background: The MINDACT (Microarray In Node-negative and 1–3 node positive Disease may Avoid ChemoTherapy) trial investigates the clinical utility of the 70-gene profile (MammaPrint) for the selection of breast cancer patients for adjuvant chemotherapy (CT) together with standard clinicopathological criteria. … Continued

Head-to-head comparison of the 70-gene signature versus the 21-gene assay: cost-effectiveness and the effect of compliance

Publication Name: Breast Cancer Research and Treatment

Author(s): Valesca P. Retel, Manuela A. Joore, Wim H. van Harten

Both the 70-gene signature and the 21-gene assay are novel prognostic tests used to guide adjuvant chemotherapy decisions in patients with early breast cancer. Although the results of ongoing prospective trials will only become available in some years, the tests … Continued

First generation prognostic gene signatures for breast cancer predict both survival and chemotherapy sensitivity and identify overlapping patient populations

Publication Name: Breast Cancer Res Treat

Author(s): Takayuki Iwamoto, Ju-Seog Lee. Giampaolo Bianchini, Rebekah E. Hubbard

The aims of this study were to compare the performance of six different genomic prognostic markers to predict long-term survival and chemotherapy response on the same patient cohort and assess if clinicopathological variables carry independent prognostic and predictive values. We … Continued

A diagnostic gene profile for molecular subtyping of breast cancer associated with treatment response

Publication Name: Breast Cancer Research and Treatment

Author(s): Oscar Krijgsman, Paul Roepman, Wilbert Zwart, Jason S. Carroll, Sun Tian, Femke A. de Snoo, Richard A. Bender, Rene Bernards, Annuska M. Glas

Classification of breast cancer into molecular subtypes maybe important for the proper selection of therapy, as tumors with seemingly similar histopathological features can have strikingly different clinical outcomes. Herein, we report the development of a molecular subtyping profile (BluePrint), that … Continued

A gene profile that identifies molecular subtypes of breast cancer is highly enriched in genes having Estrogen Receptor binding sites

Publication Name: ASCO 2011 Poster

Author(s): W. Zwart, F. De Snoo, et al

Classification of breast cancer into molecular subtypes may be important for the proper selection of therapy, as tumors with seemingly similar biology can have strikingly different clinical outcomes. We have previously developed an 80-gene molecular subtyping profile (BluePrint) for the classification of breast cancer into three … Continued

The PARSC Trial, a Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint

Publication Name: ASCO 2011 Poster

Author(s): R. Salazar, R. Rosenberg, M. Lutke Holzik, J. Marshall4 , J. J. M. Van Der Hoeven, B. Glimelius, F. Bibeau, L. Stork-Sloots

Background: An 18-gene expression profile, ColoPrint, has been developed for identifying CC patients more likely to develop recurrent disease and who would be candidates for adjuvant chemotherapy. The gene signature was validated in in-silico datasets and independent patient cohorts of stage … Continued

Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011

Publication Name: Annals of Oncology

Author(s): A. Goldhirsch, W. C. Wood, A. S. Coates, R. D. Gelber, B. Thu¨ rlimann, H.-J. Senn & Panel

The 12th St Gallen International Breast Cancer Conference (2011) Expert Panel adopted a new approach to the classification of patients for therapeutic purposes based on the recognition of intrinsic biological subtypes within the breast cancer spectrum. For practical purposes, these … Continued

Gene Expression Profiles from Formalin Fixed Paraffin Embedded Breast Cancer Tissue Are Largely Comparable to Fresh Frozen Matched Tissue

Publication Name: PLOS ONE

Author(s): Lorenza Mittempergher, Jorma J. de Ronde, Marja Nieuwland, Ron M. Kerkhoven, Iris Simon,Emiel J. Th. Rutgers, Lodewyk F. A. Wessels, Laura J. Van't Veer

Background and Methods: Formalin Fixed Paraffin Embedded (FFPE) samples represent a valuable resource for cancer research. However, the discovery and development of new cancer biomarkers often requires fresh frozen (FF) samples. Recently, the Whole Genome (WG) DASL (cDNA-mediated Annealing, Selection, … Continued